Legal & General Group
BBIO icon

Legal & General Group’s BridgeBio Pharma BBIO Stock Holding History

Legal & General Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.3M Buy
299,482
+14,565
+5% +$1.02M ﹤0.01% 832
2026
Q1 		$21.2M Sell
284,917
-49,814
-15% -$3.61M ﹤0.01% 795
2025
Q4 		$25.6M Sell
334,731
-4,759
-1% -$312K 0.01% 768
2025
Q3 		$17.6M Buy
339,490
+179,917
+113% +$8.78M ﹤0.01% 924
2025
Q2 		$6.89M Buy
159,573
+23,716
+17% +$863K ﹤0.01% 1384
2025
Q1 		$4.7M Buy
135,857
+1,819
+1% +$61.3K ﹤0.01% 1557
2024
Q4 		$3.68M Buy
134,038
+14,327
+12% +$370K ﹤0.01% 1727
2024
Q3 		$3.05M Sell
119,711
-38,511
-24% -$1.01M ﹤0.01% 1802
2024
Q2 		$4.01M Buy
158,222
+1,235
+0.8% +$33.8K ﹤0.01% 1633
2024
Q1 		$4.85M Buy
156,987
+60,022
+62% +$2.04M ﹤0.01% 1532
2023
Q4 		$3.91M Buy
96,965
+4,238
+5% +$127K ﹤0.01% 1642
2023
Q3 		$2.45M Sell
92,727
-758
-0.8% -$21.5K ﹤0.01% 1806
2023
Q2 		$1.61M Buy
93,485
+6,928
+8% +$104K ﹤0.01% 2017
2023
Q1 		$1.44M Buy
86,557
+3,479
+4% +$40.6K ﹤0.01% 2025
2022
Q4 		$633K Buy
83,078
+1,049
+1% +$10K ﹤0.01% 2279
2022
Q3 		$816K Sell
82,029
-26,246
-24% -$273K ﹤0.01% 2208
2022
Q2 		$983K Buy
108,275
+23,511
+28% +$197K ﹤0.01% 2163
2022
Q1 		$861K Sell
84,764
-1,017
-1% -$10.4K ﹤0.01% 2268
2021
Q4 		$1.43M Buy
85,781
+5,991
+8% +$253K ﹤0.01% 2144
2021
Q3 		$3.74M Buy
79,790
+13,140
+20% +$704K ﹤0.01% 1707
2021
Q2 		$4.06M Buy
66,650
+7,148
+12% +$408K ﹤0.01% 1646
2021
Q1 		$3.67M Buy
59,502
+10,270
+21% +$672K ﹤0.01% 1725
2020
Q4 		$3.5M Buy
49,232
+7,657
+18% +$369K ﹤0.01% 1657
2020
Q3 		$1.56M Buy
41,575
+23,434
+129% +$737K ﹤0.01% 1876
2020
Q2 		$590K Buy
18,141
+6,660
+58% +$203K ﹤0.01% 2128
2020
Q1 		$310K Buy
11,481
+7,036
+158% +$218K ﹤0.01% 2190
2019
Q4 		$156K Buy
4,445
+731
+20% +$20.3K ﹤0.01% 2460
2019
Q3 		$80K Buy
3,714
+3,658
+6,532% +$101K ﹤0.01% 2595
2019
Q2 		$2K Buy
+56
New +$1.53K ﹤0.01% 3478

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Legal & General Group's BBIO Position: Q2 2026 in Review

Legal & General Group increased its BridgeBio Pharma (BBIO) stake by 5.1% in Q2 2026, buying an estimated $1.02M and bringing the position to 299,482 shares worth $22.3M. The position accounts for ﹤0.01% of the portfolio, ranked #832.

Legal & General Group first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. The position peaked at $25.6M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Legal & General Group held 299,482 shares of BridgeBio Pharma worth $22.3M as of Q2 2026.
  • Legal & General Group bought 14,565 BridgeBio Pharma shares in Q2 2026, an estimated $1.02M.
  • BridgeBio Pharma made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #832 holding.
  • Legal & General Group first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
  • Legal & General Group's BridgeBio Pharma position peaked at $25.6M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.